Results 31 to 40 of about 24,588 (279)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Therapeutic Advances in Respiratory Disease, 2018
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that ...
Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano, Francesco de Blasio, Alessandro Vatrella, Girolamo Pelaia   +5 more
doaj   +1 more source

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Monaldi Archives for Chest Disease, 2020
Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the
Paolo Cameli, Miriana d'Alessandro, Laura Bergantini, Elena Silvestri, Arianna Romaldi, Giacomo Emmi, Paola Parronchi, Elena Bargagli   +7 more
doaj   +1 more source

Omalizumab and IgE in the Control of Severe Allergic Asthma

Frontiers in Pharmacology, 2022
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon, Shuichiro Maruoka, Kenji Mizumura   +2 more
doaj   +1 more source

Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis [PDF]

, 2019
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a therapeutic challenge because of the high recurrence rate. Surgical intervention should be considered in patients who fail to improve after medical treatment.
Bachert, Claus, Bosteels, Cedric, CALUS, LIEN, Dejonckheere, Sarah, Gevaert, Philippe, Holtappels, Gabriële, VAN BRUAENE, NICHOLAS, Van Zele, Thibaut   +7 more
core   +1 more source

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy, 2022
Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to European Union‐approved and United States‐licensed reference omalizumab (EU‐ and US‐omalizumab ...
Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan   +8 more
doaj   +1 more source

LINX®, a novel treatment for patients with refractory asthma complicated by gastroesophageal reflux disease: a case report. [PDF]

, 2016
BackgroundGastroesophageal reflux disease is one of the most common comorbidities in patients with asthma. Gastroesophageal reflux disease can be linked to difficult-to-control asthma.
Kenyon, Nicholas J, Kivler, Celeste, Louie, Samuel, Murin, Susan, Sriratanaviriyakul, Narin, Vidovszky, Tamas J, Yoneda, Ken Y   +6 more
core   +2 more sources

Scale‐up of a monoclonal antibody CHO fed‐batch production in stirred tank bioreactors: Effect of hydrodynamic conditions and feeding regimen

Biotechnology Progress, EarlyView.
Abstract Key hydrodynamic‐related parameters such as volumetric power input (P/V), impeller configuration, aeration strategy, and maximum gas sparge rate, as well as an appropriate feeding strategy, must be carefully selected to improve production yields in bioreactor.
Lucas Lemire, Sebastian‐Juan Reyes, Yves Durocher, Robert Voyer, Olivier Henry, Phuong Lan Pham   +5 more
wiley   +1 more source

Pediatric severe asthma: A case series report and perspectives on anti-IgE treatment [PDF]

, 2018
Background The primary goal of asthma management is to achieve disease control for reducing the risk of future exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant morbidity.
Mirra, Virginia, Montella, Silvia, Santamaria, Francesca   +2 more
core   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Acta Dermato-Venereologica
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management ...
David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau   +6 more
doaj   +1 more source